Opioid detox for Fort Lauderdale — fentanyl-era protocols, buprenorphine done right.
A specialist outpatient program for clients in Fort Lauderdale. PHP, IOP, in-house psychiatry, sober-living network, family programming. Same admissions team, 24/7.
Start the conversation Or call directly — (561) 464-4077Local options exist. This is the clinical specialist.
RECO Island is a small-census, physician-led medical detox and residential rehab campus in Delray Beach — 40 minutes north of Fort Lauderdale on I-95. Opioid detox is COWS-guided and buprenorphine-forward, with induction protocols built for fentanyl-exposed patients rather than the pre-fentanyl playbook. There are no waitlists and no third-party handoffs: clients transition directly, in-house, from medical detox into residential treatment with the same physician, therapist, and case manager throughout.
From Las Olas Boulevard or Victoria Park, RECO Island sits 40 minutes north on I-95 — close enough that Fort Lauderdale families stay involved through detox and residential care, far enough that the Delray Beach campus creates real distance from the dealers, apartments, and routines tied to active opioid use. That physical separation matters clinically: opioid use disorder is a chronic, relapsing condition, and the two weeks following detox carry the highest overdose mortality risk of any point in recovery. RECO Island’s opioid detox program is COWS-guided, buprenorphine-forward, and built for the fentanyl era, with 24/7 nursing, physician management, and a direct in-house handoff to residential treatment.
Opioid withdrawal in the fentanyl era
Fentanyl and its analogs — carfentanil, nitazenes, fluorofentanyl — have changed the clinical picture of opioid withdrawal management in ways that pre-2018 protocols do not anticipate. Fentanyl is roughly 50 times more potent than heroin and highly lipophilic, meaning it partitions into adipose tissue and re-releases into circulation over days rather than clearing within hours. The practical consequence is that withdrawal onset can be delayed and protracted, and buprenorphine induction carried out on the historical 12-24 hour timeline routinely produces precipitated withdrawal in fentanyl-exposed patients.
Xylazine adulteration compounds the picture. As a veterinary alpha-2 agonist with no opioid receptor activity, xylazine does not respond to naloxone and produces its own withdrawal syndrome — anxiety, hypertension, and characteristic necrotic wounds — layered on top of opioid withdrawal. RECO Island admissions screens for both fentanyl and xylazine exposure at intake, and treatment planning reflects what the actual toxicology shows rather than what the client believes they were using.
The result is a protocol built for what is actually on the street in 2026, not for the heroin and oxycodone era. Low-dose or Bernese micro-induction, extended clonidine bridging, and comfort medication regimens calibrated to fentanyl clearance kinetics replace the assumption that 24 hours of abstinence guarantees a safe induction window.
COWS-guided buprenorphine induction
The Clinical Opiate Withdrawal Scale (COWS) is the standard bedside instrument used across addiction medicine to quantify withdrawal severity and time buprenorphine induction. COWS scores eleven symptom domains — resting pulse, sweating, restlessness, pupil size, bone or joint aches, runny nose or tearing, GI upset, tremor, yawning, anxiety or irritability, and gooseflesh skin — with a maximum score of 48. A total of 5-12 indicates mild withdrawal, 13-24 moderate, 25-36 moderately severe, and above 36 severe.
Traditional buprenorphine induction begins once COWS crosses 11-13, confirming that mu-opioid receptors are sufficiently available for a partial agonist to bind without displacing a bolus of full agonist. Starting doses are 2-4 mg sublingually, with reassessment at 60-90 minutes and repeat dosing as indicated; total first-day dose typically reaches 8-16 mg, and steady-state maintenance settles at 16-24 mg daily for most patients. RECO Island nursing repeats COWS at defined intervals throughout induction day, and comfort medications — clonidine 0.1-0.2 mg for autonomic symptoms, loperamide for diarrhea, ondansetron for nausea, cyclobenzaprine or methocarbamol for muscle spasm, hydroxyzine or trazodone for sleep — supplement the induction rather than masking the endpoints that guide it.
Buprenorphine, methadone, or naltrexone — choosing MAT for the long run
Three medications carry strong evidence for reducing opioid overdose mortality and sustaining remission: buprenorphine, methadone, and extended-release naltrexone. Buprenorphine is a partial mu-agonist with a ceiling effect on respiratory depression, prescribed office-based (federal X-waiver requirements were eliminated in 2023), and available as daily sublingual film or monthly subcutaneous injection (Sublocade). Methadone is a full mu-agonist dispensed only through federally regulated opioid treatment programs, with the strongest evidence base but the tightest access constraints. Extended-release naltrexone (Vivitrol) is a monthly intramuscular opioid antagonist that requires a 7-10 day opioid-free window before initiation to avoid precipitated withdrawal.
The decision is not one-size-fits-all. Buprenorphine suits most patients — accessible, effective, and safer in overdose. Methadone is often the correct call for high-dose fentanyl histories, prior buprenorphine non-response, or chronic pain overlay. Naltrexone fits patients with strong antagonist preference, or occupational constraints (DOT-regulated positions, aviation, certain healthcare and safety-sensitive roles) where agonist maintenance is not permissible. RECO Island physicians make this decision collaboratively with each client during the detox stay, factoring in prior response, co-occurring depression or anxiety, discharge geography, and MAT continuation logistics before the client leaves the medical unit.
Naloxone education and the post-detox mortality window
Every RECO Island opioid detox client and their designated family contact receives structured naloxone education and a take-home prescription at discharge — this is standard of care, not optional programming. Overdose mortality is highest in the 14 days following detox, when receptor tolerance has downregulated but stress, cues, and untreated cravings can drive return-to-use. A dose that was routine two weeks earlier can be fatal.
Education covers overdose recognition (unresponsiveness, pinpoint pupils, respiratory rate below 12, cyanosis around lips and fingertips), intranasal naloxone administration, the requirement to call 911 even after a successful reversal (naloxone’s half-life is shorter than fentanyl’s, and re-narcotization is common), and rescue breathing during the reversal window. Family members and roommates are the most common first responders in overdose events, and their preparation is a substantive part of harm reduction rather than an afterthought.
Direct transition to residential — no waitlists, no handoffs
The clinical vulnerability at the tail end of detox is well characterized: withdrawal is receding, motivation is high, and a discharge into unstructured environment or a distant treatment center — with a several-day gap in between — is precisely the point at which return-to-use is most likely. RECO Island’s model eliminates that gap. Medical detox transitions directly, in-house, to residential treatment on the same Delray Beach campus, with continuity of the assigned physician, therapist, and case manager.
Residential programming layers CBT and DBT skills work, motivational interviewing, contingency management for MAT adherence, structured family sessions, and relapse-prevention planning on top of ongoing medication treatment. ASAM Criteria dimensions — acute intoxication/withdrawal, biomedical, emotional/cognitive/behavioral, readiness for change, relapse potential, and recovery environment — anchor level-of-care decisions rather than payer defaults or bed availability.
Insurance and admissions from Fort Lauderdale
RECO Island is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Admissions verifies benefits within one business day, itemizes deductible, coinsurance, and estimated out-of-pocket cost before admission, and confirms that opioid detox is authorized under the ASAM Criteria rather than an arbitrary preauthorization cap.
The admissions call from Fort Lauderdale takes 20-30 minutes and covers substance and medical history sufficient to determine medical necessity, current medications, and transport logistics. For clients in Wilton Manors, Coral Ridge, Rio Vista, or Victoria Park, transport from home to the Delray Beach campus is arranged directly, including transfer from a Fort Lauderdale hospital emergency department when appropriate. Same-day admission is standard when a bed is available and clinical indication is met.
Serving residents of: Las Olas, Victoria Park, Coral Ridge, Rio Vista, Wilton Manors.
If it's any of these, we can help.
From Fort Lauderdale callers, most asked.
Does RECO Island accept my insurance from Fort Lauderdale?
How long does opioid detox take, and what happens after?
What happens on the first day at RECO Island?
How is the decision made between buprenorphine, methadone, and Vivitrol?
How do I get to RECO Island from Fort Lauderdale?
Can my family be involved without compromising my privacy?
Other fort lauderdale-area communities we serve.
Confidential. No commitment.
Tell us a little and a real human from admissions will call you back. We verify insurance benefits within minutes and tell you honestly whether RECO Island is the right fit — including if we should refer you elsewhere.
